Chengdu Baishixing Science And Technology Industry Co., Ltd., a leading manufacturer, supplier, and factory based in China, is proud to present L-LYS(Z)-OBZL.HCL. This novel compound is a highly effective inhibitor of DPP-4, a type 2 diabetes drug target. It has been shown to possess excellent efficacy and safety profiles, and it has demonstrated promising results in preclinical and clinical studies.
L-LYS(Z)-OBZL.HCL is a synthetic amino acid derivative that acts as a competitive inhibitor of DPP-4. It exerts its therapeutic effects by increasing the levels of native incretin hormones, such as GLP-1 and GIP, which stimulate insulin secretion and reduce glucagon secretion, leading to better glycemic control.
This innovative drug candidate has the potential to revolutionize the treatment of type 2 diabetes by providing a safer and more effective alternative to the currently available therapies. It represents a major breakthrough in the field of diabetes research and underscores our commitment to developing innovative pharmaceuticals for the benefit of patients worldwide.